Leerink Partners Boosts BlossomHill Therapeutics (NASDAQ:BLSM) Price Target to $40.00

Key Points

• Leerink Partners raised BlossomHill Therapeutics’ price target from $36 to $40 while maintaining an “outperform” rating, implying 56.86% upside from the stock’s $25.50 price. Analysts overall rate the company “Moderate Buy,” with a consensus target of $35.
• BLSM shares fell 0.9% to $25.50 in Monday trading. The company reported quarterly EPS of -$8.75, missing the consensus estimate of -$0.84 by $7.91.
• Insiders have shown strong buying activity, purchasing 1.57 million shares worth $25.2 million over the past three months, including major purchases by directors Bihua Chen and Orbimed Advisors.

BlossomHill Therapeutics (NASDAQ:BLSM - Get Free Report) had its target price increased by analysts at Leerink Partners from $36.00 to $40.00 in a report issued on Monday, Benzinga reports. The firm presently has an "outperform" rating on the stock. Leerink Partners' price target indicates a potential upside of 56.86% from the stock's current price.

BLSM has been the subject of several other reports. Wall Street Zen upgraded shares of BlossomHill Therapeutics to a "hold" rating in a research report on Saturday, August 15th. Zacks Research upgraded shares of BlossomHill Therapeutics to a "hold" rating in a research report on Wednesday, September 2nd. HC Wainwright started coverage on shares of BlossomHill Therapeutics in a research note on Tuesday, September 1st. They set a "buy" rating and a $35.00 price target on the stock. Guggenheim boosted their price objective on shares of BlossomHill Therapeutics from $30.00 to $40.00 and gave the company a "buy" rating in a research report on Monday. Finally, JPMorgan Chase & Co. initiated coverage on BlossomHill Therapeutics in a research note on Tuesday, September 1st. They issued an "overweight" rating and a $28.00 price objective for the company. Five research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, BlossomHill Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus price target of $35.00.

BlossomHill Therapeutics Trading Down 0.9%

BLSM traded down $0.24 during trading on Monday, hitting $25.50. 127,478 shares of the company's stock traded hands, compared to its average volume of 223,410. BlossomHill Therapeutics has a 12-month low of $15.25 and a 12-month high of $27.99.

BlossomHill Therapeutics (NASDAQ:BLSM - Get Free Report) last posted its earnings results on Friday, September 18th. The company reported ($8.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.84) by ($7.91). Equities analysts expect that BlossomHill Therapeutics will post -3.86 earnings per share for the current year.

Insider Transactions at BlossomHill Therapeutics

In related news, Director Bihua Chen purchased 312,500 shares of BlossomHill Therapeutics stock in a transaction on Monday, August 10th. The shares were bought at an average cost of $16.00 per share, for a total transaction of $5,000,000.00. Following the acquisition, the director owned 3,614,034 shares in the company, valued at approximately $57,824,544. The trade was a 9.47% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Orbimed Advisors Llc purchased 625,000 shares of BlossomHill Therapeutics stock in a transaction on Monday, August 10th. The stock was bought at an average price of $16.00 per share, for a total transaction of $10,000,000.00. Following the completion of the acquisition, the director owned 2,714,279 shares in the company, valued at $43,428,464. The trade was a 29.91% increase in their position. The SEC filing for this purchase provides additional information. In the last three months, insiders have bought 1,573,900 shares of company stock valued at $25,181,900.

BlossomHill Therapeutics Company Profile

BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop small molecule medicines which address significant unmet medical needs in cancer treatment. The company's lead clinical programs include BH-30643. BlossomHill Therapeutics Inc is headquartered in San Diego, California.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.